SFI
MYGN icon

Susquehanna Fundamental Investments’s Myriad Genetics MYGN Stock Holding History

Susquehanna Fundamental Investments’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-66,431
Closed -$353K – 700
2025
Q2 		$353K Hold
66,431
– – 0.01% 597
2025
Q1 		$589K Buy
66,431
+47,244
+246% +$567K 0.01% 804
2024
Q4 		$263K Buy
+19,187
New +$354K ﹤0.01% 968
2024
Q2 		$2.31M Buy
+94,624
New +$2.08M 0.05% 378

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna Fundamental Investments's MYGN Position: Q3 2025 in Review

Susquehanna Fundamental Investments sold out of Myriad Genetics (MYGN) in Q3 2025, closing a stake of 66,431 shares — an estimated $353K sold.

Susquehanna Fundamental Investments first reported a position in MYGN in Q2 2024 and held it in 4 quarters. The position peaked at $2.31M in Q2 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

  • Susquehanna Fundamental Investments reported no remaining Myriad Genetics position as of Q3 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 66,431 Myriad Genetics shares in Q3 2025, an estimated $353K.
  • Susquehanna Fundamental Investments first reported a position in Myriad Genetics in Q2 2024 and held it in 4 quarters.
  • Susquehanna Fundamental Investments's Myriad Genetics position peaked at $2.31M in Q2 2024.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2025, filed 14 Nov 2025.